Simple Summary Breast cancer can express, at varied levels, a protein named HER2,
commonly responsible for making it grow and send distant metastases. In the past, patients …

Breast cancer is a heterogeneous complex of diseases, a spectrum of many subtypes with
distinct biological features that lead to differences in response patterns to various treatment …

Recently, clinical trials have demonstrated promising efficacy for novel HER2-targeted
therapies in HER2-low breast cancers, raising the prospect of including a HER2-low …

Context—HER2 is a membrane tyrosine kinase and oncogene that is overexpressed and
gene amplified in about 20% of breast cancers. When activated it provides the cell with …

Breast cancer starts as a local disease, but it can metastasize to the lymph nodes and distant
organs. At primary diagnosis, prognostic markers are used to assess whether the transition …

Animal models for examining human breast cancer (HBC) carcinogenesis have been
extensively studied and proposed. With the recent advent of immunotherapy, significant …

The year 2007 marks exactly two decades since Human Epidermal Growth Factor Receptor-
2 (HER2) was functionally implicated in the pathogenesis of human breast cancer. This …

Signalling through the ERBB/HER receptors is intricately involved in human cancer and
already serves as a target for several cancer drugs. Because of its inherent complexity, it is …

Despite extensive research over many decades, human breast cancer remains a major
worldwide health concern. Advances in pre-clinical and clinical research has led to …

Antibody-dependent cell-mediated cytotoxicity, a key effector function for the clinical efficacy
of monoclonal antibodies, is mediated primarily through a set of closely related Fcγ …